阿替利珠单抗联合贝伐单抗中由于特殊兴趣不良事件导致贝伐单抗中断的影响：III期IMbrave150研究的探索性分析
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
正在获取期刊数据...
发表日期:2024 Aug
作者:
DOI:10.1159/000535501
摘要
AI正在翻译并加载中文摘要...